Virios Therapeutics (NASDAQ:VIRI) Stock Price Down 7.3% – Should You Sell?

Virios Therapeutics, Inc. (NASDAQ:VIRI)’s stock price fell 7.3% during trading on Tuesday . The stock traded as low as $2.77 and last traded at $2.78. 39,565 shares were traded during mid-day trading, a decline of 96% from the average session volume of 1,049,645 shares. The stock had previously closed at $3.00.

Virios Therapeutics Price Performance

The business’s 50-day moving average price is $2.99 and its two-hundred day moving average price is $4.66. The company has a market capitalization of $53.54 million, a P/E ratio of -10.30 and a beta of 1.58.

Virios Therapeutics Company Profile

Virios Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for fibrotic diseases. The company leverages its proprietary small-molecule platform to identify and advance compounds designed to modulate key pathways involved in scar formation and tissue repair. By concentrating on conditions with high unmet medical need, Virios aims to improve patient outcomes through more effective and safer treatment options.

The company’s lead development candidate, VTI-1002, is an oral small molecule inhibitor in clinical trials for the prevention and treatment of hypertrophic scars and keloids.